| Outcome Measures: |
Primary: Semaglutide 7.2 mg versus Placebo: Relative change in body weight, Measured in percentage (%)., From baseline (week 0) to end of treatment (week 72)|Semaglutide 7.2 mg versus Placebo: Number of participants who achieve body weight reduction greater than or equal to (>=) 5% (yes/no), Measured as count of participants., From baseline (week 0) to end of treatment (week 72) | Secondary: Semaglutide 7.2 mg versus Placebo: Number of participants who achieve body weight reduction >=10% (yes/no), Measured as count of participants., From baseline (week 0) to end of treatment (week 72)|Semaglutide 7.2 mg versus Placebo: Number of participants who achieve body weight reduction >=15% (yes/no), Measured as count of participants., From baseline (week 0) to end of treatment (week 72)|Semaglutide 7.2 mg versus Placebo: Number of participants who achieve body weight reduction >=20% (yes/no), Measured as count of participants., From baseline (week 0) to end of treatment (week 72)|Semaglutide 7.2 mg versus Placebo: Change in waist circumference, Measured in centimeters (cm)., From baseline (week 0) to end of treatment (week 72)|Semaglutide 7.2 mg versus Placebo: Change in glycated haemoglobin (HbA1c), Measured in percentage (%)., From baseline (week 0) to end of treatment (week 72)|Semaglutide 7.2 mg versus Placebo: Change in body weight, Measured in kilograms (kg)., From baseline (week 0) to end of treatment (week 72)|Semaglutide 7.2 mg versus Placebo: Change in body mass index (BMI), Measured in kilograms per square meter (kg/m\^2)., From baseline (week 0) to end of treatment (week 72)|Semaglutide 7.2 mg versus Placebo: Change in systolic blood pressure, Measured in millimeters of mercury (mmHg)., From baseline (week 0) to end of treatment (week 72)|Semaglutide 7.2 mg versus Placebo: Change in diastolic blood pressure, Measured in mmHg., From baseline (week 0) to end of treatment (week 72)|Semaglutide 7.2 mg versus Placebo: Change in total cholesterol, Measured in ratio to baseline., From baseline (week 0) to end of treatment (week 72)|Semaglutide 7.2 mg versus Placebo: Change in high-density lipoprotein (HDL) cholesterol, Measured in ratio to baseline., From baseline (week 0) to end of treatment (week 72)|Semaglutide 7.2 mg versus Placebo: Change in low-density lipoprotein (LDL) cholesterol, Measured in ratio to baseline., From baseline (week 0) to end of treatment (week 72)|Semaglutide 7.2 mg versus Placebo: Change in very-low-density lipoprotein (VLDL) cholesterol, Measured in ratio to baseline., From baseline (week 0) to end of treatment (week 72)|Semaglutide 7.2 mg versus Placebo: Change in triglycerides, Measured in ratio to baseline., From baseline (week 0) to end of treatment (week 72)|Semaglutide 7.2 mg versus Placebo: Change in free fatty acids, Measured in ratio to baseline., From baseline (week 0) to end of treatment (week 72)|Semaglutide 7.2 mg versus Placebo: Change in high-sensitivity c reactive protein (hsCRP), Measured in ratio to baseline., From baseline (week 0) to end of treatment (week 72)|Semaglutide 7.2 mg versus Placebo: Change in fasting plasma glucose, Measured in milligrams per deciliter (mg/dL)., From baseline (week 0) to end of treatment (week 72)|Semaglutide 7.2 mg versus Placebo: Change in fasting serum insulin, Measured in ratio to baseline., From baseline (week 0) to end of treatment (week 72)|Semaglutide 7.2 mg versus Placebo: Number of participants with HbA1c less than (<) 7.0% (53 millimoles per mole [mmol/mol]), Measured as count of participants., From baseline (week 0) to end of treatment (week 72)|Semaglutide 7.2 mg versus Placebo: Number of participants with HbA1c less than or equal to (<=) 6.5 % (48 mmol/mol), Measured as count of participants., From baseline (week 0) to end of treatment (week 72)|Semaglutide 7.2 mg versus Placebo: Number of adverse events (AEs), Measured as count of events., From baseline (week 0) to end of study (week 81)|Semaglutide 7.2 mg versus Placebo: Number of serious adverse events (SAEs), Measured as count of events., From baseline (week 0) to end of study (week 81)|Semaglutide 7.2 mg versus Placebo: Change in pulse, Measured in beats per minute (bpm)., From baseline (week 0) to end of treatment (week 72)|Semaglutide 7.2 mg versus Placebo: Number of treatment emergent severe or blood glucose confirmed symptomatic hypoglycaemic episodes, Measured as count of episodes., From baseline (week 0) to end of study (week 81)|Semaglutide 7.2 mg versus Semaglutide 2.4 mg: Number of AEs, Measured as count of events., From baseline (week 0) to end of study (week 81)|Semaglutide 7.2 mg versus Semaglutide 2.4 mg: Number of SAEs, Measured as count of events., From baseline (week 0) to end of study (week 81)|Semaglutide 7.2 mg versus Semaglutide 2.4 mg: Number of treatment emergent severe or blood glucose confirmed symptomatic hypoglycaemic episodes, Measured as count of episodes., From baseline (week 0) to end of study (week 81)
|
| Locations: |
Univ of Alabama Birmingham, Birmingham, Alabama, 35222, United States|John Muir Physicians Network, Concord, California, 94520, United States|Velocity Clinical Research Westlake, Los Angeles, California, 90057, United States|Diablo Clinical Research, Inc., Walnut Creek, California, 94598, United States|New West Physicians PC, Golden, Colorado, 80401, United States|ARS- Deland CRU, DeLand, Florida, 32720, United States|Jacksonville Ctr for Clin Res, Jacksonville, Florida, 32216, United States|Florida Inst For Clin Res LLC, Orlando, Florida, 32825, United States|Oviedo Medical Research, LLC, Oviedo, Florida, 32765, United States|Hope Clin Res & Wellness, Conyers, Georgia, 30094, United States|University of North Carolina, Chapel Hill, North Carolina, 27514, United States|PharmQuest Life Sciences LLC, Greensboro, North Carolina, 27408, United States|Amarillo Med Spec LLP, Amarillo, Texas, 79106, United States|Elligo Clin Res Centre, Austin, Texas, 78704, United States|Velocity Clin Res, Dallas, Dallas, Texas, 75230, United States|UT Southwestern Medical Center - Lingvay, Dallas, Texas, 75390, United States|PlanIt Research, PLLC, Houston, Texas, 77079, United States|DCOL Ctr for Clin Res, Longview, Texas, 75605, United States|Sugar Lakes Family Practice PA, Sugar Land, Texas, 77479, United States|National Clin Res Inc., Richmond, Virginia, 23294, United States|Selma Medical Associates, Winchester, Virginia, 22601-3834, United States|"MHAT-Blagoevgrad", Department of Internal Diseases, Blagoevgrad, 2700, Bulgaria|ET "Individual practice for specialized outpatient medical care - Dr. Georgi Marinov", Burgas, 8000, Bulgaria|"Medical Center Viva Feniks" Ood, Dobrich, 9300, Bulgaria|UMHAT Pulmed, Department of endocrinology, Pazardzhik, 4400, Bulgaria|'MHAT Sveta Karidad' EAD, Plovdiv, 4004, Bulgaria|'MHAT Hadzhi Dimitar' OOD, Sliven, 8800, Bulgaria|"DCC VII - Sofia", Endocrinology Consulting Room, Sofia, 1233, Bulgaria|"UMHAT- Prof. dr. Stoyan Kirkovich", Stara Zagora, 6003, Bulgaria|"MHAT "Sveti Panteleimon" - Yambol" AD, Yambol, 8600, Bulgaria|Ocean West Research Clinic, Surrey, British Columbia, V3Z 2N6, Canada|G.A. Research Associates Ltd., Moncton, New Brunswick, E1G 1A7, Canada|Nova Scotia Hlth Halifax, Halifax, Nova Scotia, B3H 1V7, Canada|Premier Clinical Trial Research Network (PCTRN), Hamilton, Ontario, L8L 5G4, Canada|Wharton Med Clin Trials, Hamilton, Ontario, L8L 5G8, Canada|Milestone Research, London, Ontario, N5W 6A2, Canada|Lausmed Kft., Baja, Bács-Kiskun Vármegye, 6500, Hungary|Belinus Bt., Debrecen, Hajdu-Bihar Varmegye, 4025, Hungary|Borbánya Praxis E.Ü. Kft., Nyíregyháza, Szabolcs-Szatmar Varmegye, 4405, Hungary|ClinDiab Egészségügyi Szolgáltató és Kereskedelmi Kft., Budapest, 1089, Hungary|Bajcsy-Zsilinszky Kórház, Budapest, 1106, Hungary|MED-TIMA Kft., Budapest, 1132, Hungary|Fejér Megyei Szent György Oktatókórház, Székesfehérvár, 8000, Hungary|NZOZ "CenterMed Lublin" Sp. z o.o., Lublin, Lubelskie, 20-044, Poland|NZOZ Przychodnia Specjalistyczna Medica, Lublin, Lubelski, 20-538, Poland|Med. Cent. Diabet. Endo. Metabol. DIAB-ENDO-MET, Krakow, Malopolskie, 31-261, Poland|Kresmed Sp. z o. o., Bialystok, Podlaskie, 15-481, Poland|Uniwersyteckie Centrum Kliniczne SUM w Katowicach, Katowice, 40-752, Poland|NBR Polska Tomasz Klodawski, Warszawa, 00-710, Poland|PANSTWOWY INSTYTUT MEDYCZNY MSWiA, Warszawa, 02-507, Poland|Unidade Local de Saúde de Matosinhos, Senhora da Hora, Matosinhos, 4464-513, Portugal|APDP - Associação Protectora dos Diabéticos de Portugal, Lisboa, 1250-230, Portugal|Centro Hospitalar de São João, Porto, 4200-319, Portugal|DIADA s.r.o., Bardejov, 08501, Slovakia|DIADA, s.r.o., Bardejov, 08501, Slovakia|Diab - Int, s.r.o., Bytca, 014 01, Slovakia|Diabetologicka ambulancia ENDOMED, s.r.o., Kosice, 04013, Slovakia|MED-DIA CENTRUM s.r.o., Povazska Bystrica, 01701, Slovakia|DIABETOL, s.r.o., Presov, 080 01, Slovakia|Phoenix Pharma, Port Elizabeth, Eastern Cape, 6001, South Africa|Medi-Clinic Bloemfontein, Bloemfontein, Free State, 9301, South Africa|Deepak Lakha, Johannesburg, Gauteng, 1820, South Africa|Hemant Makan, Johannesburg, Gauteng, 1827, South Africa|Wits Bara Clinical Trial Site, Johannesburg, Gauteng, 2013, South Africa|Dr N.K. Gounden Medical Centre, Durban, KwaZulu Natal, 4093, South Africa|Maxwell Centre, Durban, KwaZulu-Natal, 4001, South Africa|Dr T Padayachee, Umkomaas, KwaZulu-Natal, 4170, South Africa
|
